OKMETIC OYJ STOCK EXCHANGE RELEASE 25 OCTOBER 2011 AT 8.00 A.M.

OKMETIC INTERIM REPORT 1 JANUARY - 30 SEPTEMBER 2011

Unless otherwise stated, figures in parenthesis refer to the corresponding period in the previous year.

#### JULY-SEPTEMBER IN BRIEF:

- Net sales amounted to 21.3 (21.6) million euro, down 1.7%.
- Operating profit was 4.0 (3.7) million euro corresponding to 19.0% of net sales.
- Profit for the period was 2.9 (3.8) million euro.
- Basic earnings per share were 0.18 (0.23) euro.
- Net cash flow from operations amounted to 2.1 (5.6) million euro.

#### JANUARY-SEPTEMBER IN BRIEF:

- Net sales amounted to 65.1 (57.8) million euro, up 12.5%.
- Operating profit was 9.5 (7.0) million euro corresponding to 14.6% of net sales.
- Profit for the period was 8.2 (7.8) million euro.
- Basic earnings per share were 0.49 (0.47) euro.
- Net cash flow from operations amounted to 6.3 (9.9) million euro.

#### PROJECTIONS FOR 2011

The balancing of the electronics industry components' stock levels will also continue during the rest of the year, which means a mild demand for semiconductors until the end of the year. Instead, market projections for sensor wafers, especially for SOI wafers are stable. The structural change which started in the solar cell industry in the spring continues, and the rapidly lowered price level is likely to continue the consolidation of the business. Okmetic's operation as a solar cell industry supplier is largely based on long-term shipment agreements, which protects the company from the strongest market changes. As a whole, the last quarter of the year will be the weakest of 2011 in terms of net sales as well as operating profit.

The company confirms the existing guidance, according to which the net sales and operating profit of 2011 are estimated to exceed the level of 2010.

#### PRESIDENT KAI SEIKKU:

"Okmetic's third quarter of the year went excellently considering the fact that the market conditions have become more difficult. In July-September, operating profit amounted to 4.0 million euro while net sales declined slightly and amounted to 21.3 million euro. Operating profit percent (19.0%) reached the highest level in the company's recent history despite the fact that no license income from technology sales was obtained during the period, but the net sales consisted entirely of component and material sales. The positive profit development of the company will enable the company to fully make use of the losses, which have been confirmed in Finland during earlier financial periods, in the taxation concerning the 2011 financial period. The deferred tax assets recognised from tax losses no longer had any impact on the result in July-September.

The semiconductor market decelerated during this period in which the demand has traditionally been the strongest of the year, and the normal peak in demand due to seasonal fluctuation was not experienced. The phenomenon is noticeable in the division of Okmetic's sales per customer area, where the share of sensor wafers (44%) at the end of the third quarter was at the same level as in the beginning of the year. The relative share of Asia (38%) was on the increase, partly due to structural reasons, and partly because of the significant slowing down of the North American market.

The reason behind the slowing of the semiconductor industry's demand is, in particular, the problems of the macro economy, which create caution in the electronics industry and make its value chain balance the stock levels inflated in the first half of 2011. The balancing is likely to continue over the turn of the year, and the company predicts that the demand will rise again in the second quarter of next year. The outlook will be updated once the market prospects become clearer.

There are three key factors behind good profitability: cost control, flexible (fab lite) supply chain, and investment in demanding sensor wafers, in particular in SOI wafers, the record delivery volumes of which contributed to the good sales margin. Long-term shipment agreements protected Okmetic from the rough price competition going on in the solar cell industry. The price competition is a consequence of the global overcapacity, high stock levels, rapid migration of production to China and the Far East, and the solar power plant projects' funding insecurities caused by the financial crisis.

Okmetic's strong balance, profitability, and cash flow are likely to further strengthen the company's competitive position and market shares when demand starts to increase again. However, growth is sought in all market situations. A sales office serving the important Asian market outside Japan has been opened in Hong Kong. The investment important for the future, which was announced in late spring, and which aims at a significant increase in SOI wafers' production capacity and productivity, is proceeding as planned. The company also invests selectively in other growing product groups, such as the epi deposition of wafers used for power semiconductor production. The epi

deposition takes place at the Allen production plant in the United States."

#### KEY FIGURES

1,000 euro	1.7 30.9.11	1.7 30.9.10	1.1 30.9.11		
Net sales Operating profit before	21,250	21,626	65,052	57,835	80,907
depreciation (EBITDA) Operating	5 <b>,</b> 580	5 <b>,</b> 368	14,222	12,052	17,102
<pre>profit % of net sales Profit for</pre>	4,045 19.0	3,712 17.2	9,480	6,981 12.1	10,421 12.9
the period Basic earnings	2,941	3,793	8,247	7,806	9,952
per share, euro Net cash flow from operating	0.18	0.23	0.49	0.47	0.60
activities Net interest bearing	2,094	5,573	6,260	9,864	16,594
liabilities Equity ratio, % Average number	-11,642 79.3	-12,752 78.7			•
of personnel during the period	373	358	365	347	345

#### MARKETS

Customer industries sensor, semiconductor, and solar cell industries

#### Sensor industry

In 2011, the sale value of sensor industry is estimated to grow 11-15 percent compared to the sale value of 2010 (7.1-8.6 billion US dollars). One of the fastest growing sectors is MEMS products for consumer applications such as microphones, gyroscopes, and picoprojectors (IHS, iSuppli, Yole). Nowadays, silicon-on-insulator (SOI) technology is already widely used in the manufacture of these next generation products, and the share of SOI technology is estimated to continue its growth. Okmetic is amongst the pioneering suppliers who provide products and services based on SOI technology to the sensor industry.

## Semiconductor industry

The semiconductor industry's sales in US dollars have deteriorated further during the third quarter of the year. The estimates for the sale development have continued to decline and adjusted between 2.9 and -0.2 percent of yearly growth (iSuppli, Gartner, SIA).

In the third quarter of this year, the market cycle's annual peak typical for the industry did not take place, and the industry is not predicted to return to a clear growth track until the latter half of 2012 (Gartner). The estimated growth of sales for 2012 settles at a level of 3-5 percent (iSuppli, Gartner).

The demand for semiconductors is maintained by a group of rapidly growing applications, led by tablet computers, SSD hard discs, and smart phones (Gartner). In the long run, the growth rate of semiconductor demand is estimated to remain at a yearly level of 8-9 percent. The growth rate of power semiconductors is estimated to exceed the semiconductor market average (IC Insights).

## Solar cell industry

Although the industry's demand grew during the third quarter, the supply was clearly greater than the demand. Oversupply and high stock levels have led to still clearly declining prices throughout the industry's supply chain. The unfavourable market situation is expected to continue for the next few months.

#### Silicon wafer market

According to the estimate published in September 2011 by SMG, the group of silicon wafer suppliers in SEMI, the volume of wafer shipments in the entire silicon wafer industry in 2011 equals the shipment volumes of 2010. Compared to the ongoing year, a growth of 4 percent is estimated for 2012.

Okmetic's central customer areas in the silicon wafer market

In line with its strategy, Okmetic seeks for special areas of the entire silicon wafer market that have greater growth rates than the market average and in which the company has special know-how. Okmetic supplies primarily 150mm and 200mm wafers. The sensor/MEMS industry is Okmetic's central growth area. The MEMS market grows as the portable consumer products, automotive electronics, and industrial process control increase.

In the semiconductor market, Okmetic's growth areas include discrete and power semiconductors. The growth areas of these markets are i.a. components used in the production of renewable energy, increasing automotive electronics, portable consumer products, developing applications of the medical and well-being industries as well as industrial process controlling.

#### SALES

In January-September, Okmetic's net sales increased by 12.5 (42.6) percent from the previous year amounting to 65.1 (57.8) million euro. The growth of net sales was supported especially by good sensor industry demand. Okmetic succeeded to increase its market share in the product groups which are important to the company.

	1.7	1.7	1.1	1.1	1.1
	30.9.11	30.9.10	30.9.11	30.9.10	31.12.10
Sensors	44%	42%	44%	43%	43%
Semiconductors	36%	45%	36%	43%	42%
Technology	20%	13%	20%	14%	15%

In January-September, the value of sensor wafer shipments was 15.4 percent higher than in the corresponding period last year.

The semiconductor industry's weakening trend affected the semiconductor wafer sales during the third quarter of the year. In January-September, the shipment value of these wafers was 5.7 percent lower than in the corresponding period last year.

In January-September, technology sales comprised mainly of solar crystal sales. The solar cell industry's market change had only minor effects on Okmetic's operations in the third quarter. Okmetic's shipment volumes continued to be strong and were 1.2 million euro higher than in the corresponding quarter last year.

## Sales per market area

	1.7	1.7	1.1	1.1	1.1
	30.9.11	30.9.10	30.9.11	30.9.10	31.12.10
North America	35%	46%	36%	43%	43%
Europe	27%	25%	29%	26%	25%
Asia	38%	29%	35%	31%	32%

The proportion of Europe of the total net sales grew during January-September. The proportion of Asia of the total net sales grew during July-September.

#### PROFITABILITY

## July-September

In July-September, Okmetic's operating profit was 4.0 (3.7) million euro. The operating profit accounted for 19.0 (17.2) percent of net sales. There are three key factors behind good profitability: cost control, flexible (fab lite) supply chain, and the record delivery volumes of SOI wafers. Profit for the period amounted to 2.9 (3.8) million euro. Basic earnings per share were 0.18 (0.23) euro.

## January-September

In January-September, Okmetic's operating profit was 9.5 (7.0) million euro. The operating profit accounted for 14.6 (12.1) percent of net sales. Profit for the period amounted to 8.2 (7.8) million euro. Basic earnings per share were 0.49 (0.47) euro.

#### FINANCING

The company's financial situation is good. In January-September, net cash flow from operations amounted to 6.3 (9.9) million euro.

On 30 September 2011, the company's liabilities amounted to 1.0 (1.0) million euro. At the end of the period, cash and cash equivalents amounted to 12.6 (13.8) million euro. On 30 September 2011, the company's cash and cash equivalents exceeded interest-bearing liabilities by 11.6 million euro (on 30 September 2010, cash and cash equivalents were 12.8 million euro higher than interest-bearing liabilities).

Return on equity amounted to 18.4 (19.9) percent. The company's equity ratio was 79.3 (78.7) percent. Equity per share was 3.69 (3.35) euro.

#### INVESTMENTS

In January-September, Okmetic's capital expenditure amounted to 7.5 (0.7) million euro. The investments concern mainly the board's decision in April 2011 to increase SOI wafer production capacity by extending the Vantaa plant. The around 30 million euro investment programme includes the plant extension and different kinds of production equipment. Building of the plant extension started in August.

This investment, together with the SOI equipment investments decided earlier, more than triples the Vantaa plant's current SOI wafer production capacity.

#### PRODUCT DEVELOPMENT

In January-September, the company expensed 1.7 (1.4) million euro in product development projects. Product development costs accounted for 2.7 (2.4) percent of net sales. The product development costs have not been capitalised. Product development has been allocated to sensor wafers and crystal growing that are important to Okmetic.

#### PERSONNEL

On average, Okmetic employed 365 (347) people in January-September. At the end of the period, 313 of the company's employees worked in Finland, 34 in the US, and three in Japan.

#### BUSINESS RISKS IN THE NEAR FUTURE

As the uncertainty in the world economy continues, the most significant factors causing uncertainty for Okmetic's business in the near future are related to the sensitivity of semiconductor wafer demand to economic fluctuations and to the rapid and strong changes in the market situation. The company only has considerable pricing power with its own special products. The

pricing of other wafers is mainly based on global market price. The most common trade currency in the field is the US dollar. The company's result is affected by the US dollar's strong currency changes against the euro.

The fact that Okmetic's main production facilities are located in the relatively expensive euro zone places cost pressure for the company. Other challenges include maintaining market leadership position in the company's own special fields, together with meeting the demand gearing towards bigger wafer sizes.

The company risks and uncertainty factors are dealt more profoundly in the company's annual report of 2010.

#### SHARES AND SHAREHOLDERS

On 30 September 2011, Okmetic Oyj's paid-up share capital, as entered in the Finnish trade register, was 11,821,250 euro. The number of shares was 17,287,500. The shares have no nominal value attached. Each share entitles its holder to one vote at general meeting. The company has one class of shares.

#### SHARE PRICE DEVELOPMENT AND TRADING

A total of 9.3 (8.4) million shares were traded between 1 January and 30 September 2011, representing 53.6 (48.6) percent of the weighted average of share total of 17.3 million during the period. The lowest quotation of the reporting period was 3.50 (2.98) euro, and the highest 6.65 (5.04) euro, with the average being 5.58 (3.76) euro. The closing quotation for the period was 4.67 (4.82) euro. At the end of the period, the market capitalisation amounted to 80.7 (83.3) million euro.

#### OWN SHARES

At the end of the period, the company held a total of 207,848 shares, which is approximately 1.2 percent of Okmetic's all shares and votes.

Okmetic's board of directors decided on 5 August 2011, based on an existing authorisation of the board of directors, to repurchase a maximum of 280,000 company's own shares. The share repurchase started on 16 August 2011. An aggregate number of 151,137 shares were repurchased in the period under review, corresponding to approximately 0.9 percent of the total number of Okmetic shares and votes. A total of 711,700.33 euro was used for the repurchase, and the average purchase price per share was 4.71 euro.

The repurchased shares may be used in developing the company's capital structure, as compensation in possible corporate acquisitions or in other business arrangements, as part of the company's incentive scheme or transferred or cancelled in other ways.

On 18 August 2011, Okmetic Oyj's board of directors announced of its decision to transfer 9,432 own shares held by the company, for free, to a member of the executive management group belonging to Okmetic's share-based incentive scheme 2010-2011, as a proportion of reward to be paid as shares on the basis of earning period 2010.

CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 30 SEPTEMBER 2011 (unaudited)

#### ACCOUNTING POLICIES

These interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting.

In preparing these interim financial statements, Okmetic has followed the same accounting policies as in the financial statements for 2010 except for the effect of changes required by the adoption of the following new or revised standards and interpretations as of 1 January 2011:

IAS 24 (revised), Related Party Disclosures
IAS 32 (amendment), Financial Instruments: Presentation Classification of Rights Issues
IFRIC 19, Extinguishing Financial Liabilities with Equity
Instruments
IFRIC 14 (amendment), Prepayments of a Minimum Funding
Requirement
Improvements to IFRSs, May 2010

The adoption of the aforementioned standards and interpretations has not had an effect on the figures presented from the reporting period.

Okmetic has applied hedge accounting as defined in IAS 39 to the electricity derivative contracts entered into after 1 April 2011 hedging highly probable forecast cash flows associated with electricity purchases. The effective portion of changes in the fair value of derivatives that are designated as cash flow hedges is recognised in other comprehensive income and presented in hedge reserve, which is included in "Other reserves" in equity. Such accumulated fair value changes are reclassified to the income statement in the periods when the hedged cash flow affects profit or loss. The gain or loss relating to the ineffective portion is recognised immediately in the income statement within other operating income and expenses.

From the start of 2011 Okmetic has changed the place where changes in fair values of currency derivative contracts and their realised profits and losses are presented in the statement of comprehensive income. In line with the new policy, the changes in the fair values of currency derivative contracts and their realised profits and losses are presented with the financial income and expenses. Previously these items were presented with other operating income and expenses. Okmetic has reported of the

change in accounting policies on the interim report published on  $27\ \text{April}\ 2011.$ 

## CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

1,000 euroa		30 Sep,			
Net sales			65,052		80,907
Cost of sales Gross profit	-15,473		-48,488	-44,491	-62,274 18,633
Other income and expenses Operating	-1,732	-2,602	-7,084	-6,364	-8,212
profit Financial	4,045	3,712	9,480	6,981	10,421
income and expenses Profit before	72	-777	-580	-142	-610
tax Income tax	4,117 -1,176	2,934 859	8,900 -653	6 <b>,</b> 839 967	9,811 141
Profit for the period	2,941	3 <b>,</b> 793	8,247	7 <b>,</b> 806	9 <b>,</b> 952
Other comprehensive income:					
Cash flow hedges Translation	-13	-	-33	_	-
differences Other comprehensive income for the	598	-456	339	506	624
period, net of tax	584	-456	305	506	624
Total comprehensive income for the period	3 <b>,</b> 526	3 <b>,</b> 337	8 <b>,</b> 553	8,312	10,576
Profit for the period attributable to: Equity holders					
of the parent company	2,941	3 <b>,</b> 793	8,247	7 <b>,</b> 806	9,952

Total comprehensive income

attributable to:					
Equity holders					
of the parent company	3,526	3,337	8,5	53 8 <b>,</b> 312	10,576
	,	,	-, -	.,.	, ,
Basic earnings					
per share,					
euro	0.18	0.23	0.	49 0.47	0.60
Diluted					
earnings per share, euro	0 17	0.23	$\circ$	48 0.47	0.58
Share, euro	0.17	0.23	0.	40 0.47	0.50
CONDENSED CONSOLI	DATED BAI	LANCE SHEE	T		
1 000		2.0	~	20.0	21 5
1,000 euro			Sep, 2011	30 Sep, 2010	31 Dec, 2010
		•	2011	2010	2010
Assets					
Non-current asse	ts				
Property, plant					
and equipment			,776	29,102	29,069
Other receivable		3,	,977	4,124	2,441
Total non-curren	t				
assets		35,	,753	33,226	31,510
Current assets					
Inventories		11,	,911	9,424	9,987
Receivables		17,	,724	14,691	15 <b>,</b> 674
Financial assets					
at fair value th	rough				
profit or loss			_	_	5,004
Cash and cash		1.0	C 4 O	10 755	14 042
equivalents Total current as:	a o + a		,642 ,277	13,755 37,870	14,043 44,708
Total Cullent as	sers	42,	,	37,070	44,700
Total assets		78,	,030	71,096	76 <b>,</b> 217
Equity and liabi	lities				
Equity					
Equity attributal					
equity holders of	f the				
parent company		1.1	0.01	11 001	11 001
Share capital			,821	11,821	11,821
Other equity			<b>,</b> 755	44,040	46,420
Total equity		<b>6</b> Γ '	,576	55,861	58,242
Liabilities					
Non-current liab	ilities	2,	,092	2,543	1,245
Current liabilit			,361	12,692	16,730
Total liabilities	S	16,	, 453	15,235	17,976

Total equity and

liabilities	78,030	71,096	76,217
TIGNITICE	10100	, ± , 0 0 0	, 0, 2 - ,

## CONDENSED CONSOLIDATED CASH FLOW STATEMENT

1,000 euro	1 Jan- 30 Sep, 2011	1 Jan- 30 Sep, 2010	1 Jan- 31 Dec 2010
Cash flows from operating			
activities:			
Profit before tax	8,900	6 <b>,</b> 839	9,811
Adjustments	6,080	5,409	6 <b>,</b> 795
Change in working	0.006	0.054	0.1.0
capital	-8 <b>,</b> 286	•	210
Financial items	-407		-279
Tax paid Net cash from	-26	85	58
operating activities	6 <b>,</b> 260	9,864	16,594
operating activities	0,200	9,004	10,094
Cash flows from investing activities:			
Purchases of property,			
plant and equipment	-6 <b>,</b> 986	-636	-2,173
Investments in fixed	F 016		F 000
income funds	5,016	_	-5 <b>,</b> 000
Net cash used in	-1,970	-636	-7,173
investing activities	-1,970	-030	-/,1/3
Cash flows from financing			
activities:			
Repayments of			
long-term borrowings	_	-1,500	-1,500
Payments of finance			
lease liabilities	_	-36	-39
Share issue	_	1,200	1,200
Repurchase of own shares	-664	-1,868	-1,868
Dividends paid	-5 <b>,</b> 043	-834	-834
Net cash used in			
financing activities	-5 <b>,</b> 707	-3 <b>,</b> 038	-3,041
T			
<pre>Increase(+) / decrease ( ) in cash and cash</pre>			
<pre>(-) in cash and cash equivalents</pre>	-1,416	6 <b>,</b> 190	6,381
Exchange rate changes	-1 <b>,</b> 410	258	355
Cash and cash	10	250	333
equivalents at the			
beginning of the period	14,043	7,307	7,307
Cash and cash	,	,	,
equivalents at the			
end of the period	12,642	13,755	14,043

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

1,000 euro	Equity att Share capital	ributable Share pre- mium	to equity Reserve for in- vested unre- stricted equity	Other re-	parent com Retained earnings	pany Total
Balance at 31 Dec, 2010	11,821	20,045	1,200	1,039	24,137	58,242
Profit for the period Other com- prehensive income, net of tax: Cash flow					8,247	8,247
hedges Translation				-33		-33
differences Total com- prehensive income for				339		339
the period				305	8,247	8 <b>,</b> 553
Repurchase of own					664	
shares Share based					-664	-664
payments Dividend					489	489
distribution Balance at	11 001	20 045	1 200	1 244	-5 <b>,</b> 043	<b>-5,</b> 043
30 Sep, 2011	11,821	20,045	1,200	1,344	27 <b>,</b> 166	61 <b>,</b> 576
Balance at 31 Dec, 2009 Profit for	11,821	20,045	-	415	16,461	48,742
the period Other com- prehensive income, net					7,806	7,806
of tax: Translation						
differences Total com- prehensive				506		506
income for the period				506	7 <b>,</b> 806	8,312
Share issue Repurchase			1,200			1,200
of own shares					-1,868	-1,868
Share based payments					309	309
Dividend distribution					-834	-834
Balance at 30 Sep, 2010	11,821	20,045	1,200	921	21,874	55,861

<sup>1) &</sup>quot;Other reserves" contains hedge reserve and translation differences.

# CHANGES IN PROPERTY, PLANT AND EQUIPMENT

1,000 euro	1 Jan- 30 Sep, 2011	30 Sep,	
Carrying amount at the beginning of the period Additions Disposals Depreciation Exchange differences Carrying amount at the end of the period	29,069	33,174	33,174
	7,519	678	2,232
	-	-2	-74
	-4,742	-5,071	-6,681
	-70	323	419
	31,776	29,102	29,069
COMMITMENTS AND CONTINGENCIES			
1,000 euro	30 Sep,	30 Sep,	31 Dec,
	2011	2010	2010
Loans, secured with collaterals Collaterals Off-balance sheet lease commitments	1,000	1,000	1,000
	8,073	8,073	8,073
Capital commitments	4,823	2,354	2,190
Nominal values of derivative contracts Currency options, call Currency options, put Currency forward agreements Electricity derivatives	2,729	2,400	15,244
	652	-	18,034
	-	1,318	-
	2,515	1,773	2,038
Fair values of derivative contracts Currency options, call Currency options, put Currency forward agreements Electricity derivatives	13	205	184
	-72	-	-595
	-	-4	-
	-63	-45	544

The contract price of the derivatives has been used as the nominal value of the underlying asset.

## KEY FIGURES SHOWING FINANCIAL PERFORMANCE

1,000 euro	1 J	an- 1	Jan-	1 Jan-
	30 S	ep, 30	Sep, 3	1 Dec,
	2	011	2010	2010

Net sales Change in net sales	65 <b>,</b> 052	57 <b>,</b> 835	80,907
compared to the previous			
year's period, %	12.5	42.6	48.8
Export and foreign	12.0	12.0	10.0
operations share			
of net sales, %	94.7	95.9	95.8
Operating profit before	J 4 • 1	J J • J	JJ • 0
depreciation (EBITDA)	14,222	12,052	17,102
% of net sales	21.9	20.8	21.1
	9,480		
Operating profit % of net sales	·	6 <b>,</b> 981	10,421
	14.6	12.1	12.9
Profit before tax	8,900	6 <b>,</b> 839	9,811
% of net sales	13.7	11.8	12.1
Return on equity, %	18.4	19.9	18.6
Return on investment, %	19.5	17.4	18.2
Non-interest-bearing			
liabilities	15,453	14,232	16 <b>,</b> 976
Net interest-bearing			
liabilities	-11,642		-18 <b>,</b> 047
Net gearing ratio, %	-18.9	-22.8	-31.0
Equity ratio, %	79.3	78.7	76.6
Capital expenditure	7,519	678	2,232
% of net sales	11.6	1.2	2.8
Depreciation	4,742	5 <b>,</b> 071	6,681
Research and development			
expenditure	1,729	1,414	2,110
% of net sales	2.7	2.4	2.6
Average number of			
personnel during			
the period	365	347	345
Personnel at the		0 1 /	0.10
end of the period	350	340	342
ena of the period	330	310	J 12
KEY FIGURES PER SHARE			
TELL LICOTED LEIK DILIKE			
Euro	30 Sep,	30 Sep,	31 Dec,
	2011	2010	2010
	2011	2010	2010
Basic earnings			
per share	0.49	0.47	0.60
Diluted earnings	0.13	0.17	0.00
per share	0.48	0.47	0.58
Equity per share	3.69	3.35	3.49
Dividend per share	J. 0 J	J.JJ	0.30
	_	_	51.7
Dividends/earnings, % Effective dividend	_	_	JI. /
			5.7
yield, %	<del>-</del>	_	
Price/earnings(P/E)	<del>-</del>	_	8.9
Chara parformance (1 Tan )			
Share performance (1 Jan-)	E E0	276	4 00
Average trading price	5.58	3.76	4.22
Lowest trading price	3.50	2.98	2.98

Highest trading price Trading price at the	6.65	5.04	5.70
end of the period Market capitalisation	4.67	4.82	5.29
at the end of the			
period, 1,000 euro	80,733	83,326	91,451
Trading volume			
(1 Jan-)			
Trading volume,			
transactions, 1,000 pcs	9 <b>,</b> 268	8,361	14,009
In relation to weighted			
average number of			
shares, %	53.6	48.6	81.4
Trading volume,			
1,000 euro	51 <b>,</b> 732	31,466	59 <b>,</b> 124
The weighted average			
number of shares during			
the period under review			
adjusted by the share			
issue, 1,000 pcs	17 <b>,</b> 288	17 <b>,</b> 197	17,220
The number of shares at			
the end of the period			
adjusted by the share			
issue, 1,000 pcs	17 <b>,</b> 288	17,288	17,288

When calculating earnings per share (EPS) and equity, Okmetic's own shares in its possession and Okmetic's shares owned by Okmetic Management Oy are deducted from the amount of shares.

# QUARTERLY KEY FIGURES

1,000 euro	10-12/ 2011	7-9/ 2011	4-6/ 2011	
Net sales		21,250	21,747	22,055
Compared to previous quarter, % Compared to corresponding		-2.3	-1.4	-4.4
period last year, %		-1.7	10.5	33.5
Operating profit		4,045	2,606	2,828
% of net sales		19.0	12.0	12.8
Profit before tax		4,117	2,487	2,296
% of net sales		19.4	11.4	10.4
Net cash flow generated from:				
Operating activities		2.094	5,503	-1,337
Investing activities		•	1,035	•
Financing activities Increase/decrease in cash			-5,043	_
and cash equivalents		330	1,495	-3,243

Personnel at the end

of the period		350	389	351
1,000 euro		7-9/ 2010		
Net sales	23,072	21,626	19,688	16,521
Compared to previous quarter, % Compared to corresponding	6.7	9.8	19.2	19.6
period last year, %	67.0	77.7	45.4	11.3
Operating profit	3,440	3,712	2,481	788
% of net sales	14.9	17.2	12.6	4.8
Profit before tax	2,972	2,934	2 <b>,</b> 987	918
% of net sales	12.9	13.6	15.2	5.6
Net cash flow generated from:				
Operating activities	6 <b>,</b> 730	5 <b>,</b> 573	1,874	2,417
Investing activities		-547		
Financing activities	-3		-2,406	
Increase/decrease in cash				
and cash equivalents	191	5,021	-599	1,767
Personnel at the end of the period	342	340	373	329

## MAJOR SHAREHOLDERS ON 30 SEPTEMBER 2011

	Shares, pcs	Share,
Ilmarinen Mutual Pension		
Insurance Company	1,666,601	9.6
Mandatum Life Insurance Company		
Limited	807 <b>,</b> 700	4.7
The State Pension Fund	600,000	3.5
Veritas Pension Insurance		
Company Ltd.	491,393	2.8
Varma Mutual Pension		
Insurance Company	477 <b>,</b> 175	2.8
Okmetic Management Oy	400,000	2.3
Etra-Invest Oy Ab	400,000	2.3
Nordea Nordic Small Cap Fund	370,660	2.1
Aktia Secura Fund	335,681	1.9
Sijoitusrahasto Taaleritehdas		
Arvo Markka Osake	225,100	1.3
Kaleva Mutual Insurance		
Company	212,700	1.2
Okmetic Oyj	207 <b>,</b> 848	1.2
Sijoitusrahasto Aktia Capital	165,387	1.0
Mutual Fund Evli Finnish		
Equity	142,700	0.8
EQ Pikkujättiläiset /		

EQ Rahastoyhtiö	140,000	0.8
SR Arvo Finland Value	110,611	0.6
Kiilholma Antti Tapio	90,093	0.5
OP-Finland Small Firms Fund	80,000	0.5
Stenhäll Turo	75,000	0.4
Virtanen Yhtiöt Oy	70,000	0.4
Nominee registered shares	3,014,528	17.4
Others	7,204,323	41.7
Total	17,287,500	100.0

# DEFINITIONS OF KEY FINANCIAL FIGURES

Operating profit before depreciation (EBITDA)	= Operating profit + depreciation
Return on equity (ROE), %	= Profit/loss for the period from continuing operations x 100/ Equity(Average for the period)
Return on investment (ROI), %	= (Profit/loss before tax + interest and other financial expenses) x 100/ Balance sheet total - non-interest bearing liabilities (average for the period)
Equity ratio, %	= Equity x 100/ Balance sheet total - advances received
Net interest-bearing liabilities	= Interest-bearing liabilities - cash and cash equivalents
Net gearing ratio, %	= (Interest-bearing liabilities - cash and cash equivalents) x 100/ Equity
Earnings per share	= Profit/loss for the period attributable to equity holders of the parent company/ Adjusted weighted average number of shares in issue during the period
Equity per share	= Equity attributable to equity holders of the parent company/ Adjusted number of shares at the end of the period
Dividend per share	<pre>= Dividend for the period/   Adjusted number of shares at the end of the period</pre>
Effective dividend yield, %	= Dividend per share x 100/ Trading price at the end of the period
Price/earnings ratio (P/E)	= Last adjusted trading price at the end of the period/ Earnings per share
Average trading price	= Total traded amount in euro/ Adjusted number of shares traded during the period

the end of the period

Trading volume

Market capitalisation at = Number of shares at the end of the period xtrading price at the end of the period

> = Number of shares traded during the period/ Weighted average number of shares during the period

All figures of the financial tables are rounded, and consequently the sum of individual figures can deviate from the presented sum figure. The figures are unaudited.

The future estimates and forecasts in this interim report are based on company management's current knowledge. Actual events and results may differ from the estimates presented here.

#### PRESS CONFERENCE

A press conference for the media and analysts will be held on Tuesday, 25 October 2011 at 9.30 a.m. at Okmetic's head office: Piitie 2, 01510 Vantaa. The result will be presented by President Kai Seikku. The press conference will be held in Finnish.

We ask participants to kindly give advance notice of their attendance by email to communications@okmetic.com or by telephone to +358 9 5028 0406/Marika Mäntymaa.

OKMETIC OYJ

Board of directors

For further information, please contact:

President Kai Seikku, Okmetic Oyj, tel. +358 400 200 288, email: kai.seikku@okmetic.com

Senior Vice President, Finance, IT, and Communications Juha Jaatinen, Okmetic Oyj, tel. +358 9 5028 0286, email: juha.jaatinen@okmetic.com

Distribution: NASDAQ OMX Helsinki Principal media www.okmetic.com

OKMETIC IN BRIEF

Take it higher

Okmetic is a technology company which supplies tailor-made silicon wafers for sensor and semiconductor industries and sells its technological expertise to the solar cell industry. Okmetic provides its customers with solutions that boost their competitiveness and profitability.

Okmetic's silicon wafers are part of a further processing chain that produces end products that improve human interaction and quality of life. Okmetic's products are based on high-tech expertise that generates added value for customers, innovative product development and an extremely efficient production process.

Okmetic has a global customer base and sales network, production plants in Finland and the US and contract manufacturers in Japan and China. Okmetic's shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more information on the company, please visit our website at www.okmetic.com.